Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CTSG | P08311 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096091 | 0.84 | CYP4F2 (0.58) | CYP4F2CYP4A11MMP9ALDH1A1NPC1 | |
| SCHEMBL119585 | 0.83 | LMNA (0.54) | CYP4F2CYP4A11ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL343527 | 0.83 | IDO1 (0.56) | CYP4F2CYP4A11ALDH1A1NPC1RAB9A | |
| SCHEMBL4113212 | 0.82 | CYP4F2 (0.76) | CYP4F2CYP4A11ALDH1A1NPC1RAB9A | |
| SCHEMBL257153 | 0.82 | MMP9 (0.57) | CYP4F2CYP4A11MMP9ALDH1A1NPC1 | |
| SCHEMBL10141348 | 0.82 | CYP4F2 (0.56) | CYP4F2CYP4A11MMP9ALDH1A1NPC1 | |
| SCHEMBL22664337 | 0.82 | CA2 (0.58) | CYP4F2CYP4A11ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL16092814 | 0.82 | CYP4F2 (0.56) | CYP4F2CYP4A11MMP9ALDH1A1NPC1 | |
| SCHEMBL8934772 | 0.81 | MTNR1A (0.42) | CYP4F2CYP4A11MMP9ALDH1A1KDM4E | |
| SCHEMBL12440455 | 0.81 | ALDH1A1 (0.60) | CYP4F2CYP4A11ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | PHENEX PHARMACEUTICALS AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | US | disclosed |
| CN-113666853-B | Biaryl compounds useful as ROR gamma modulators | 上海辉启生物医药科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20220402867-A1 | SULFO-SUBSTITUTED BIARYL COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI LITEDD CO., LTD. (CN) | 2022-12-22 | — | — | US | disclosed |
| US-20220402867-A1 | SULFO-SUBSTITUTED BIARYL COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI LITEDD CO., LTD. (CN) | 2022-12-22 | — | — | US | disclosed |
| EP-4039674-A1 | SULFO-SUBSTITUTED BIARYL COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Litedd Co., Ltd. (CN) | 2022-08-10 | — | — | EP | disclosed |
| US-11364220-B2 | Compounds and methods for inhibiting CPY26 enzymes | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2022-06-21 | — | — | US | disclosed |
| CN-112851557-B | Sulfo-substituted biaryl compound or salt thereof, and preparation method and application thereof | 上海辉启生物医药科技有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-114502532-A | Sulfo-substituted biaryl compound or salt thereof, and preparation method and application thereof | 上海辉启生物医药科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-109651208-B | N-aryl sulfonamide compound, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2022-01-04 | — | — | CN | disclosed |
| US-20090274632-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof | SENOMYX, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| CN-101443348-A | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2009-05-27 | — | — | CN | disclosed |
| US-20090088368-A1 | COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS | IRM LLC (BM) | 2009-04-02 | — | — | US | disclosed |
| US-20090088368-A1 | COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS | IRM LLC (BM) | 2009-04-02 | — | — | US | disclosed |
| WO-2009025793-A2 | HUMAN T2R BITTERNESS RECEPTORS AND USES THEREOF | SENOMYX, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| EP-2019837-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2009-02-04 | — | — | EP | disclosed |
| WO-2007140117-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2007-12-06 | — | — | WO | disclosed |
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274632-A1 | Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof | TAS2R50, TAS2R1, TAS2R30 | CYP4F2 938/4885CYP4A11 2225/4885MMP9 4736/4885 |
| US-20220402867-A1 | SULFO-SUBSTITUTED BIARYL COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | RORB, RORA, RORC | CYP4F2 132/4885CYP4A11 7/4885MMP9 3961/4885 |
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | PRSS1, PRSS8, PRSS2 | CYP4F2 4061/4885CYP4A11 3313/4885MMP9 140/4885 |
| US-11364220-B2 | Compounds and methods for inhibiting CPY26 enzymes | CYP2A6, CYP27A1, CYP26B1 | CYP4F2 23/4885CYP4A11 59/4885MMP9 3394/4885 |
| US-20230357214-A1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | NR1H2, NR1H3, NR1H4 | CYP4F2 1149/4885CYP4A11 122/4885MMP9 4476/4885 |
| US-20090088368-A1 | COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS | PPARG, PPARA, PPARD | CYP4F2 1420/4885CYP4A11 923/4885MMP9 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.